Erratum: Contemporary analysis of the influence of acute kidney injury after reduced intensity conditioning haematopoietic cell transplantation on long-term survival (Bone Marrow Transplantation (2008) 10.1038/bmt.2008.207);Contemporary analysis of the influence of acute kidney injury after reduced intensity conditioning haematopoietic cell transplantation on long-term survival

Bone Marrow Transplantation

Volumn 42, Issue 9, 2008, Pages 619-626

  Lopes, J A ^a   Goncalves S ^a   Jorge, S ^a   Raimundo, M ^a   Resende, L ^a   Lourenco F ^a   Lacerda, J F ^a   Martins, C ^a   do Carmo, J A ^a   Lacerda, J M F ^a   Prata, M M ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN A; CYTARABINE; FLUCONAZOLE; FLUDARABINE; MELPHALAN; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE KIDNEY INJURY; ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY INJURY; LONG TERM CARE; MAJOR CLINICAL STUDY; MORTALITY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

EID: 56349164626     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.341     Document Type: Erratum

References (38)

1. Giralt S, Thall PF, Khouri I, Wang X, Brauschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
2. Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P et al Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6: 309-320.
3. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-763.
4. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
5. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J et al Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295: 527-535.
6. Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: Directing graft-versus-leukemia at solid tumors. Cancer J 2002; 8: 2-11.
7. Uzunel M, Mattsson J, Brune M, Johansson JE, Aschan J, Ringden O. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 2003; 101: 469-472.
8. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by haematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
9. Hermann S, Klein SA, Jacobi V, Thalhammer A, Bialleck H, Duchscherer M et al. Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens. Br J Haematol 2001; 113: 446-454.
10. Blaise D, Bay JO, Faucher C, Michallet M, Boiron J-M, Chou. B et al Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435-441.
11. Saito T, Kanda Y, Kami M, Kato K, Shoji N, Kanai S et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 2002; 8: 1014-1020.
12. Belkacemi Y, Labopin M, Hennequin C, Hoffstetter S, Mungai R, Wygoda M et al. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys 2007; 67: 544-551.
13. Zager RA, O'Quigley J, Zager BK, Alpers CE, Shulman HM, Gamelin LM et al. Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients. Am J Kidney Dis 1989; 13 210-216.
14. Merouani A, Shpall EJ, Jones RB, Archer PG, Schrier RW. Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int 1996; 50: 1026-1031.
15. Parikh CR, McSweeney PA, Korular D, Ecder T, Merouani A, Taylor J et al. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int 2002; 62: 566-573.
16. Parikh CR, McSweeney P, Schrier RW. Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant. Kidney Int 2005; 67: 1999-2005.
17. Kersting S, Koomans HA, Hené RJ, Verdonck LF. Acute renal failure after allogeneic myeloablative stem cell transplantation: Retrospective analysis of incidence, risk factors and survival. Bone Marrow Transplant 2007; 39: 359-365.
18. Lopes JA, Jorge S, Silva S, de Almeida E, Abreu F, Martins C et al An assessment of the RIFLE criteria for acute renal failure following myeloablative autologous and allogeneic haematopoietic cell transplantation. Bone Marrow Transplant 2006; 38: 395.
19. Lopes JA, Jorge S, Gonçalves S, Resina C, Silva S, de Almeida E et al. Contemporary analysis of the influence of acute kidney injury (AKI) after myeloablative hematopoietic cell transplantation on long-term patient's survival. Bone Marrow Transplant 2008; 42 139-142.
20. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky and the ADQI workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-R212.
21. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al., the Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
22. Maris M, Sandmaier BM, Maloney DG, McSweeney PA, Woolfrey A, Chauncey T et al. Non-myeloablative haematopoietic stem cell transplantation. Transfus Clin Biol 2001; 8: 231-234.
23. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before haematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550-1558.
24. Parikh CR, Sandmaier BM, Storb RF, Blume KG, Sahebi F, Maloney DG et al. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol 2004; 15: 1868-1876.
25. Parikh CR, Schrier RW, Storer B, Diaconescu R, Sorror ML, Maris MB et al. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis 2005; 45 502-509.
26. Kersting S, Dorp SV, Theobald M, Verdonck LF. Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant 2008; 14: 125-131.
27. Parikh CH, Yarlagadda SG, Storer B, Sorror M, Storb R, Sandmaier B. Impact of acute kidney injury on long-term mortality after nonmyeloblative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14: 309-315.
28. Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: An update. Curr Opin Nephrol Hypertens 2001; 10: 785-792.
29. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292: 895-902.
30. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006; 34: 1913-1917.
31. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: A cohort analysis. Crit Care 2006; 10: R73-R82.
32. Ostermann M, Chang RWS. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007; 35: 1837-1843.
33. Lassnigg A, Scmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: A Prospective Cohort Study. J Soc Am Nephrol 2004; 15: 1597-1605.
34. Bagshaw SM, Mortis G, Doig CJ, Godinez-Luna T, Fick GH, Laupland KB. One-year mortality in critically ill patients by severity of kidney function: A population-based assessment. Am J Kidney Dis 2006; 48: 402-409.
35. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M et al. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006; 17: 2034-2047.
36. Weiss AS, Sandmaier BM, Storer B, Storb R, Mc Sweeney PA, Parikh CR. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant 2006; 6: 89-94.
37. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489-1494.
38. Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol 2003; 14: 1549-1558.